1
|
Ericson MD, Tran LT, Mathre SS, Freeman KT, Holdaway K, John K, Lunzer MM, Bouchard JL, Haskell-Luevano C. Discovery of a Pan-Melanocortin Receptor Antagonist [Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH 2] at the MC1R, MC3R, MC4R, and MC5R that Mediates an Increased Feeding Response in Mice and a 40-Fold Selective MC1R Antagonist [Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH 2]. J Med Chem 2023; 66:8103-8117. [PMID: 37307241 PMCID: PMC10631449 DOI: 10.1021/acs.jmedchem.3c00432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Discovery of pan-antagonist ligands for the melanocortin receptors will help identify the physiological activities controlled by these receptors. The previously reported MC3R/MC4R antagonist Ac-DPhe(pI)-Arg-Nal(2')-Arg-NH2 was identified herein, for the first time, to possess MC1R and MC5R antagonist activity. Further structure-activity relationship studies probing the second and fourth positions were performed toward the goal of identifying potent melanocortin antagonists. Of the 21 tetrapeptides synthesized, 13 possessed MC1R, MC3R, MC4R, and MC5R antagonist activity. Three tetrapeptides were more than 10-fold selective for the mMC1R, including 8 (LTT1-44, Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH2) that possessed 80 nM mMC1R antagonist potency and was at least 40-fold selective over the mMC3R, mMC4R, and mMC5R. Nine tetrapeptides were selective for the mMC4R, including 14 [SSM1-8, Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH2] with an mMC4R antagonist potency of 1.6 nM. This compound was administered IT into mice, resulting in a dose-dependent increase in the food intake and demonstrating the in vivo utility of this compound series.
Collapse
Affiliation(s)
- Mark D Ericson
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Linh T Tran
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Sarah S Mathre
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Katie T Freeman
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Kelsey Holdaway
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Kristen John
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Mary M Lunzer
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Jacob L Bouchard
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Carrie Haskell-Luevano
- Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States
| |
Collapse
|
2
|
Mass OA, Tuccinardi J, Woodbury L, Wolf CL, Grantham B, Holdaway K, Pu X, King MD, Warner DL, Jorcyk CL, Warner LR. Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery. Sci Rep 2021; 11:16174. [PMID: 34376712 PMCID: PMC8355150 DOI: 10.1038/s41598-021-95424-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 07/05/2021] [Indexed: 02/07/2023] Open
Abstract
Oncostatin M (OSM) is a pleiotropic, interleukin-6 family inflammatory cytokine that plays an important role in inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer progression and metastasis. Recently, elevated OSM levels have been found in the serum of COVID-19 patients in intensive care units. Multiple anti-OSM therapeutics have been investigated, but to date no OSM small molecule inhibitors are clinically available. To pursue a high-throughput screening and structure-based drug discovery strategy to design a small molecule inhibitor of OSM, milligram quantities of highly pure, bioactive OSM are required. Here, we developed a reliable protocol to produce highly pure unlabeled and isotope enriched OSM from E. coli for biochemical and NMR studies. High yields (ca. 10 mg/L culture) were obtained in rich and minimal defined media cultures. Purified OSM was characterized by mass spectrometry and circular dichroism. The bioactivity was confirmed by induction of OSM/OSM receptor signaling through STAT3 phosphorylation in human breast cancer cells. Optimized buffer conditions yielded 1H, 15N HSQC NMR spectra with intense, well-dispersed peaks. Titration of 15N OSM with a small molecule inhibitor showed chemical shift perturbations for several key residues with a binding affinity of 12.2 ± 3.9 μM. These results demonstrate the value of bioactive recombinant human OSM for NMR-based small molecule screening.
Collapse
Affiliation(s)
- Olga A. Mass
- grid.184764.80000 0001 0670 228XBiomoleculer Research Center, Boise State University, Boise, ID 83725 USA
| | - Joseph Tuccinardi
- grid.184764.80000 0001 0670 228XDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Dr., Boise, ID 83725 USA
| | - Luke Woodbury
- grid.184764.80000 0001 0670 228XBiomoleculer Research Center, Boise State University, Boise, ID 83725 USA
| | - Cody L. Wolf
- grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XDepartment of Biological Sciences, Boise State University, Boise, ID 83725 USA
| | - Bri Grantham
- grid.184764.80000 0001 0670 228XBiomoleculer Research Center, Boise State University, Boise, ID 83725 USA
| | - Kelsey Holdaway
- grid.184764.80000 0001 0670 228XDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Dr., Boise, ID 83725 USA
| | - Xinzhu Pu
- grid.184764.80000 0001 0670 228XBiomoleculer Research Center, Boise State University, Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA
| | - Matthew D. King
- grid.184764.80000 0001 0670 228XDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Dr., Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA
| | - Don L. Warner
- grid.184764.80000 0001 0670 228XDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Dr., Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA
| | - Cheryl L. Jorcyk
- grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XDepartment of Biological Sciences, Boise State University, Boise, ID 83725 USA
| | - Lisa R. Warner
- grid.184764.80000 0001 0670 228XBiomoleculer Research Center, Boise State University, Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Dr., Boise, ID 83725 USA ,grid.184764.80000 0001 0670 228XBiomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725 USA
| |
Collapse
|
3
|
Crosier PS, Skinner M, Le Gros G, Holdaway K, Watson JD. Growth of fetal thymocytes in organ culture: effect of recombinant lymphokines on thymocyte maturation. Growth Factors 1989; 1:299-310. [PMID: 2483921 DOI: 10.3109/08977198909000254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Interleukin 2 (IL2) has a dose-dependent inhibitory effect on the growth and phenotypic maturation of thymocyte populations grown in fetal thymus organ culture. Addition of IL2 (100 U/ml) to 14-day fetal thymus organ cultures induces the appearance of a population of lymphokine-activated killer (LAK) cells which lyse allogeneic, syngeneic, and syngeneic tumor cell targets. The addition of the monoclonal antibody, PC-61, blocks the IL2-dependent growth and activation of LAK cells but does not influence the maturation of CD4+ CD8+ fetal thymocytes. These data imply that IL2 is not a major regulator of normal fetal thymocyte maturation. The effects of a range of recombinant lymphokines (IL1 alpha, IL1 beta, IL3, IL4, GM-CSF, G-CSF, M-CSF) on the proliferation and phenotypic maturation of fetal 14-day thymocytes in organ culture has been analysed. Two significant changes were seen. First, IL1 alpha and IL1 beta inhibited growth and the expression of the CD4 and CD8 antigens in organ culture, and second, GM-CSF increased the expression of Mac-1+ cells. IL4, which has known T cell growth-promoting activity, IL3, G-CSF, and M-CSF did not alter either normal growth or surface antigen expression in fetal thymocytes. While some of these lymphokines may function as accessory molecules in fetal thymocyte development, our experiments suggest that they do not have a significant influence on thymocyte maturation when used alone.
Collapse
Affiliation(s)
- P S Crosier
- Department of Immunobiology, School of Medicine, University of Auckland, New Zealand
| | | | | | | | | |
Collapse
|